Avrobio Inc., a clinical-stage gene therapy company, completed a review of its business, including the status of its programs, resources, and capabilities. Avrobio has decided to halt further development of its programs and conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, Avrobio will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combi...